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topics, understandability, and feasibility of use. Based on the
above steps, a preliminary instrument was created for valida-
tion testing. RESULTS: Key themes generated from literature,
clinicians, and families included various aspects of pain, difﬁ-
culty using the device, embarrassment, and time involved
affecting productivity, convenience, and compliance. Two ver-
sions of the preference instrument were created to reﬂect the
child and parent perspectives. A 4-point Likert scale was used
for most questions. The child version included 38 survey items
on clarity of instructions (2), preparation (7), administration
(4), convenience (3), pain (5), embarrassment (2), anxiety (2),
productivity (4), compliance (3), mood (1), and overall satis-
faction (5). All items from the child questionnaire were
included in the parent version, supplemented with ﬁve ques-
tions regarding administration, parent productivity, and parent
overall satisfaction. CONCLUSION: Areas of concern for fami-
lies using GH delivery devices include pain, productivity, and
convenience. This new instrument, which may offer clinicians
and researchers an opportunity to evaluate different device
alternatives for GH replacement therapy, will soon undergo
formal validation testing.
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OBJECTIVE: To assess the association between the DM-39 and
HbA1c in a large insulin clinical trial (acronym: DURABLE)
where HbA1c is a primary efﬁcacy endpoint. METHODS: The
DURABLE trial enrolled insulin-naïve type 2 diabetes patients
then randomized them to lispro mix 75/25 bid or glargine qd.
Trial participants completed the DM-39 at baseline prior to
receiving insulin. The DM-39 is a 39-item diabetes-speciﬁc
PRO measure with 5 domains: Energy/Mobility (15-item), Dia-
betes Control (12-item), Anxiety/Worry (4-item), Social Burden
(5-item), and Sexual Function (3-item). Each domain’s score
ranged from 0–100 with a higher score representing worse
PRO. We used Spearman’s correlation to assess the overall
association with HbA1c. We also conducted analysis of vari-
ance (ANOVA) with pairwise comparisons using Scheffe adjust-
ment to compare the mean scores reported by patients with
baseline HbA1c <8.0% (group A); 8.0–8.9% (B); 9.0–9.9%
(C); and >10% (D). RESULTS: A trial subgroup of 867
patients (mean age = 56.8 years, duration of diabetes = 9.6
years, HbA1c = 8.9%. 42% female, 65% Caucasian) provided
the data. Correlations with HbA1c were low (r range: 0.01–
0.18) with Diabetes Control (r = 0.18), Anxiety/Worry
(r = 0.10), and Social Burden (r = 0.11) resulting in statistically
signiﬁcant correlations (p < 0.01). Overall ANOVA p-values
were statistically signiﬁcant for Diabetes Control (mean scores
for groups A, B, C, and D = 37.5, 39.7, 43.7, and 46.2, respec-
tively, p < 0.001); Anxiety/Worry (41.5, 42.2, 48.5, and 47.0,
p = 0.003); and Social Burden (22.2, 21.6, 25.5, and 28.3,
p < 0.001). Pairwise comparisons were statistically signiﬁcant
for Diabetes Control (A vs. C, A vs. D, and B vs. D); Anxiety/
Worry (A vs. C); and Social Burden (A vs. D and B vs. D).
CONCLUSION: DM-39 is weakly associated with HbA1c.
However, our ﬁndings suggest that some targeted domains (e.g.,
Diabetes Control) may be useful in assessing the changes in
PRO for clinical trials evaluating insulin initiation with a
primary endpoint of HbA1c.
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OBJECTIVE: The study evaluated the impact of a doctor’s or a
health professional’s instructions on lifestyle behaviors among
the US adult diabetic population. METHODS: The study popu-
lation was adult diabetic subjects in the latest National Health
and Nutrition Examination Survey (NHANES) 2005–2006.
Multivariate logistic regression was employed adjusting for the
survey design using STATA software. A total of 459 diabetic
subjects aged 18 and over were enrolled, which represented
about 15 million US adults with diabetes. The three dichotomous
categorical independent variables of interest were whether the
subject had been told by their doctor or health professional in the
last year to lower their risk of certain diseases by controlling
weight, by increasing physical activity, or by reducing fat or
calorie intake. The outcomes of interest were whether action was
currently being taken by the subject to follow that past advice.
RESULTS: After controlling potential confounders (including
demographics, education, and disease severity), it was found that
subjects who were told by their doctor or health professional to
lose weight were more likely to be working on weight control,
compared with those not told to do so (p < 0.001). Similar results
were found for exercise advice (p = 0.001) and diet advice
(p = 0.002). This cross-sectional analysis cannot conﬁrm causal-
ity and recall bias cannot be eliminated. CONCLUSION: The
study suggests that advice by a doctor or a health professional
has great impact on diabetic patients to take actions in changing
their lifestyle behaviors.
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OBJECTIVE: Differences between patient-rated importance of
insulin delivery system (IDS) features and patient evaluation of
those features in current IDS may contribute to patient satisfac-
tion. This study aimed to examine: 1) the importance of 12 IDS
features to patients with type 2 diabetes (T2DM); 2) the dis-
crepancies between feature importance and patient evaluation
of those features in current IDS; 3) the relationship between
discrepancies and IDS satisfaction. METHODS: Patients with
T2DM currently using insulin were administered a web-based
survey including questions on demographics, insulin therapy, and
a modiﬁed Insulin Injection Preference questionnaire (mIIP-q).
ThemIIP-q asks patients to evaluate the extent towhich they agree
their current IDS has each of the 12 features representing 3
components (“ease of use,” “activity interference,” and “social
acceptability”). Patients were also asked to rank and rate the
importance of the 12 IDS features. Discrepancy scores were
calculated by subtracting the feature importance score from the
feature evaluation score. Correlation and stepwise linear regres-
sion analyses were conducted to assess the relationship between
discrepancy scores and IDS satisfaction.RESULTS:A total of 681
patients (48%male, mean age = 57) participated in the survey. All
IDS features in the mIIP-q were considered important (mean
rating >50 on a 0–100 scale). The feature “easy to control blood
sugar” showed the highest discrepancy score, followed by all
“activity interference” features (P < 0.01). Discrepancy scores for
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all 12 features were associated with IDS satisfaction (P < 0.01),
but only discrepancy scores for “easy to control blood sugar,”
“reduces my reluctance to use insulin,” “easy to get insulin dose
needed,” and “convenient to use” were signiﬁcant predictors of
IDS satisfaction, as were HbA1C and health status (R2 = 0.31;
P < 0.05).CONCLUSION: IDS features are important to patients
with T2DM; therefore resolving discrepancies between feature
importance and patient evaluation of IDS features may improve
patient satisfaction and facilitate diabetes management.
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OBJECTIVE: Understanding what Insulin Delivery System (IDS)
features are important to patients with type 2 diabetes (T2DM) is
essential to the development of improved IDSs. The objective of
this study was to determine what characteristics are associated
with (or predict) users of insulin pens vs. vial and syringe
(V/S). METHODS: Patients with T2DM were administered a
web-based survey that included questions about demographics,
comorbidities, glycemic control, and insulin use; ratings of the
importance of 12 IDS features; and an evaluation of features of the
current IDS. Two logistic regression analyses were performedwith
the respondent characterization of their IDS as insulin pen or V/S
as dependent variables. Variables signiﬁcantly (p < 0.05) associ-
ated with dependent variables, a priori, were included as indepen-
dent variables. RESULTS: A total of 681 insulin-using
T2 patients in the US (52% female; mean age = 57 years; 88%
Caucasian; 85% on insulin >1 year, 86% used V/S) participated in
the survey. Signiﬁcant predictors (p < 0.05) for insulin pen use:
Patient: “is a homemaker” (OR, 0.177), “agrees their IDS does
not interfere with plans for short trips” (OR, 5.942), “agrees their
IDS is easy to carry away from home” (OR, 0.054), “rates their
IDS ease to carry away from home as ‘important’” (OR, 2.558),
“uses Byetta” (OR, 0.067), “injects insulin >twice/day” (OR,
0.235), “has never been diagnosed with depression” (OR, 0.367).
Signiﬁcant predictors (p < 0.05) of V/S use: Patient: “is dissatisﬁed
with their IDS regarding insulin use” (OR, 111.767), “disagrees
their IDS makes it easy getting ready for next dose” (OR, 0.006),
“has cancer” (OR, <0.0001), “uses Glargine” (OR, <0.0001), “is
not using insulin lispro” (OR, 0.013), “has a higher number of
adults in the household”, “rates IDS discreetness as ‘least impor-
tant’ ” (OR, 206.347). CONCLUSION: Overall, multiple injec-
tions and need for portability predict insulin pen use; not valuing
discreteness and dissatisfaction predict V/S use.
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OBJECTIVE: To examine the effects of sociodemographic
characteristics, health status, comorbidity, provider, medication
and ﬁnancial variables on insulin initiation behavior for type 2
diabetics on multiple oral antidiabetic medications. METHODS:
The 2002–2006 MarketScan Research Databases were used to
study the health care utilization and expenditure patterns of
adults with type 2 diabetes in employer-sponsored health plans in
the United States. The utilization patterns of 38,768 patients
with Type 2 diabetes who were adherent to one oral antidiabetic
medication and added a second oral medication for at least 6
months were analyzed. Two outcomes were examined: insulin
initiation within 12 months and the amount of time to insulin
initiation. Multivariate logistic models were used to estimate the
effects of the explanatory variables on the likelihood of insulin
initiation. Cox proportional hazard models with prescription
drug and ofﬁce visit copayments as time-varying covariates were
used to estimate the effects of the explanatory variables on the
amount of time to insulin initiation. RESULTS: A total of 16.5%
of patients initiated insulin within one year. A variety of deter-
minants were associated with insulin initiation within a year: age
(Adjusted Odds Ratio 0.982, 95% CI (0.980, 0.985) ), health
status indicated by the presence of factors such as heart disease
(AOR 1.48 (1.317, 1.654)), myocardial infarction (AOR 1.32,
(1.068, 1.640)), diabetic retinopathy (AOR 1.26, (1.120,
1.406)), the number of nondiabetes medications (AOR 1.03,
(1.030, 1.039)), and insulin copayments (AOR 0.998, (0.995,
1.000)). The amount of time to insulin initiation was also
affected by similar factors. CONCLUSION: Health status
appears to be the strongest predictor of insulin initiation in
patients initiating insulin for type 2 diabetics who are adherent to
oral medications. Providers, health plans and employers should
be aware of the factors that inﬂuence the addition of a medica-
tion to a treatment regimen for chronically-ill patients.
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OBJECTIVE: To evaluate the one to two year changes in health
care costs and disease-related process measures associated with
the a disease management program initiated in 2002 for
higher-risk, higher-expenditure adult fee-for-service Medicaid
clients with diabetes in the State of Colorado, United States.
METHODS: This retrospective database analysis employed a
pre-post and propensity-score matched analysis assessing direct
costs from the perspective of a public payer. Data analyzed
included comprehensive medical and pharmacy claims, patient
demographics (i.e., age, gender, race), medical and pharmacy
resource utilization claims (e.g., selected prescription drug use
and laboratory testing procedures conducted), diagnostic
information, and eligibility/enrollment status. Multivariate re-
gression techniques were utilized to ascertain differences between
the disease management and matched comparator groups.
RESULTS: Of the 388 Medicaid clients that were eligible and
initially contacted for enrollment, 41 (11%) completed at least
one year and 10 (3%) completed an entire two years of the
program. Enrollees were typically older, female, and of a non-
white race or ethnicity. Among those enrolled for one year or
more, signiﬁcant decreases in overall medical costs were observed
relative to matched comparators during both Year 1 and Year 2
of the interventions (Year 1 = 44.4% decrease, p < 0.001 and
Year 2 = 67.1% decrease, p < 0.010). Overall pharmacy costs
were lower for the disease management group during Year 2
(64.0% decrease, p = 0.013), as were diabetes-related pharmacy
costs (64.9%, p = 0.005). Effect sizes based upon multivariate
analyses were observed to be small. CONCLUSION: Based on
this analysis of 41 clients completing at least one year of diabetes
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